Actinium Pharmaceuticals Highlights Presence at the Society of Hematologic Oncology 2017 Annual Meeting
September 13, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Company’s Actimab-A and Actimab-M programs to be presented at the conference NEW YORK, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc (NYSE American:ATNM) (“Actinium” or “the...
Actinium to Present at The Rodman & Renshaw 19th Annual Global Investment Conference
September 06, 2017 16:05 ET
|
Actinium Pharmaceuticals
NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
August 02, 2017 16:05 ET
|
Actinium Pharmaceuticals
Actinium raised total gross proceeds of $16.125 million NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a...
Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
July 28, 2017 09:10 ET
|
Actinium Pharmaceuticals
NEW YORK, July 28, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Stock
July 27, 2017 16:05 ET
|
Actinium Pharmaceuticals
NEW YORK, July 27, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals Highlights Presence at Upcoming Society of Nuclear Medicine and Molecular Imaging Annual Meeting
June 08, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Society of Nuclear Medicine and Molecular Imaging to be held June 10 – 14, 2017 in Denver, Colorado - Actinium to conduct webinar to provide an update on its Pivotal Phase 3 drug...
Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors
March 28, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Proven leader with 36 years of experience with Johnson & Johnson in numerous executive capacities, most recently as Head of Enterprise Supply Chain- Dr. Shetty was instrumental in establishing...
Actinium Pharmaceuticals to Present at 29th Annual ROTH Conference
March 07, 2017 07:00 ET
|
Actinium Pharmaceuticals
NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology Platform
February 28, 2017 07:00 ET
|
Actinium Pharmaceuticals
Allowed patent application claims methods for generating radioimmunoconjugates linked to Actinium-225 Patent expected to expire in July 2030 NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) --...
Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
February 21, 2017 07:00 ET
|
Actinium Pharmaceuticals
- Industry veteran to lead development of optimized programs for Iomab-B including initiatives targeted at patients, physicians and payors designed to support clinical development and...